Verastem, Inc. (VSTM)
NASDAQ • Healthcare
Last close at October 23, 2026 at 20:00 UTC
Metrics Over Time
Where the Money Goes
Q2 2026In plain terms: out of every $100 in revenue, Verastem, Inc. currently loses $87.
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Nov 5
in 11 daysQ4 2026% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Verastem’s EPS topped expectations in the second fiscal quarter of 2026, reported August 6, 2026, with EPS of -$0.35 topping the -$0.43 estimate by $0.08 as revenue surged 1775.4% year over year to about $40.1 million (up from about $2.1 million a year ago). Gross profit came in around $36.0 million, supporting a gross margin of roughly 90%, while operating income was a loss of about $32.7 million and operating margin was -81.6%. Net income was a loss of roughly $34.7 million, down 33.7% year over year from a loss of about $25.9 million. Cash generation remained negative, with negative operating cash flow of about $43.9 million. For the next period, consensus calls for EPS of -$0.44 on revenue of $29.1 million.
Next report — what to expect
Verastem, Inc. (VSTM) is set to report earnings on November 3, 2026. Coming into the release, its recent results show it has beaten EPS in 5 of its 8 most recent quarters, a track record traders may weigh alongside any updates on the period’s key drivers and outlook when the report hits.
About Verastem, Inc.
Verastem, Inc. is a NASDAQ-listed biotechnology company developing targeted cancer medicines, centered on the clinical candidates VS-6766 and defactinib. The company generated $30.9 million of revenue in FY2025 and operates in the biopharmaceutical research and development business rather than commercial-scale drug manufacturing.
Today's Snapshot
VSTM closed slightly lower at 10.04, while its sector was weaker. Volume was about two-fifths of its usual level.
Trading Volume
Below 10d avg (8.4M)
3.7M
vs S&P 500 Today
Moderate Outperformance
+0.32%
Updated: October 23, 2026 at 20:23 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$7.00 - $9.10Buy
- RSI (14)67.22Neutral
- Stochastic %K (14, 3, 3)92.09Sell
- MACD Level (12, 26)0.53Buy
Peers & Related Assets
Get premium market insights delivered directly to your inbox.